Government Action

$50-100k grants to address socioeconomic outcome disparities due to AMR-related factors

Dear All, I was fascinated to see Mayo Clinic’s Global Bridges Healthcare Alliance release an RFP on 21 Oct entitled “Antimicrobial Stewardship (AMS) Programs to Address Health Inequities arising from Socioeconomic Disparities in USA, Europe, Japan, South Korea, Australia and New Zealand.” The RFP is supported by a grant from Pfizer and seeks to “… solicit programs that have

Read More »

WHO Tripartite Joint Secretariat on AMR seeks consultant to develop multisectoral guidance

Dear All, WHO continues on their streak of seeking support for their AMR-related work! Today we have a posting by the Tripartite Joint Secretariat on Antimicrobial Resistance (AMR) of a consultancy opening for an 11-month project that would support development of multisectoral guidance(s) on development and strengthening of the coordination mechanisms and governance structures for addressing AMR. Full details

Read More »

Building momentum for delinked incentives: Key upcoming webinars

Dear All, A brief note today as I am traveling (yes, really … first time in almost 18 months) but wanted to share these 3 important upcoming meetings. The theme I expect to hear running through them all is that (i) innovation is possible (the CARB-X Year 5 report is amazing!), (ii) new antibiotics must both

Read More »

Antibiotic supply chains: Challenges & Opportunities

Dear All, In a report entitled Understanding the Antibiotic Manufacturing Ecosystem: A view of global supply chains, pressure points, and implications for antimicrobial resistance response, the Boston Consulting Group and Wellcome Trust have examined at length the questions of (i) how the #FireExtinguishersOfMedicine are made and (ii) how they can be made with the least impact

Read More »

NIAID BAA To Support In Vitro Diagnostic Product Development

Dear All, Excitingly, NIAID has released a new BAA (Broad Agency Announcement) entitled “Diagnostics Pre-Clinical Services Program.” Similar to the prior BAA for support of biopharmaceutical product development, this new BAA for diagnostic devices seeks a group who can manage a “multiple award Indefinite Delivery/Indefinite Quantity (IDIQ) type contract” (read that slowly!) and through it offer a comprehensive

Read More »

UK Pull (Netflix) pilot: QALY value of new antibiotics implies societal value > 10m GBP/year!

Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), We’ve written before about the UK’s “Netflix” pilot antibiotic Pull incentive in which England leads the way on showing how it plans to provide its fair share of a global antibacterial Pull incentive (for background on Pull incentives, see this superb 5-minute video explainer). In

Read More »

WHO-FAO-OIE-UNEP survey on a multi-stakeholder AMR platform

Dear All (this newsletter experiments with an Executive Summary/Details format; let me know what you think),  (Executive Summary)  As a further support for implementation of recommendations from the UN Interagency Coordination Group on Antimicrobial Resistance (IACG AMR), the Tripartite Plus (WHO-FAO-OIE-UNEP) are seeking to create a Partnership Platform that will “engage institutions representing states, markets and

Read More »

Comment on US 2023-2026 National Health Security Strategy

Dear All, The US Office of the Assistant Secretary for Preparedness & Response (ASPR) is looking for comments on the 2023-2026 National Health Security Strategy (NHSS). They would like input from stakeholders in public health, healthcare, emergency management, national security, non-governmental organizations, academia, and private industry.  Their specific questions to consider are: What are the most critical national health

Read More »

Sign a letter in support of antifungal R&D … in support of PASTEUR!

Dear All: As you know if you are a regular reader of this newsletter, I think that creation of suitable Pull incentives by passage of the PASTEUR Act in the United States is key to building a vibrant pipeline of products to address the international problem of AMR. I’ve also written recently about the FORWARD Act

Read More »

EMA-FDA-PMDA action + Podcasts (CDD, Pew) + NEJM on non-inferiority

Dear All: Several updates today, all on the theme of good things to know or share! First, EMA, FDA, and PMDA are continuing to meet and have released a summary of their third tripartite meeting. The key message is alignment: alignment on trial designs for key indications, alignment on pediatric programs, and alignment on single global development programs! This is

Read More »
Scroll to Top